SCHEMBL20023063

SCHEMBL20023063

CC(C)c1ccc(C(=O)CCCC(=O)C(=O)OCc2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP5 P45974 1/20 0.50
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
DPP4 P27487 1/20 0.44
LMNA P02545 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
BCHE P06276 1/20 0.42
PDE4B Q07343 1/20 0.42
EGFR P00533 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20023064 0.97 USP5 (0.50) USP5RAB9ANPC1SMN1; SMN2RXRA
SCHEMBL20023099 0.92 USP5 (0.56) USP5RAB9ANPC1SMN1; SMN2RXRA
SCHEMBL20023040 0.87 TDP1 (0.56) RAB9ANPC1DPP4LMNAKMT2A
SCHEMBL20023029 0.86 L3MBTL1 (0.51) RAB9ANPC1DPP4LMNAKMT2A
SCHEMBL20023090 0.85 PDE4B (0.46) RAB9ANPC1DPP4LMNAKMT2A
SCHEMBL20023052 0.85 DPP4 (0.46) RAB9ANPC1RXRARXRBDPP4
SCHEMBL20023032 0.84 TDP1 (0.58) RAB9ANPC1DPP4LMNAKMT2A
SCHEMBL20023091 0.84 PDE4B (0.63) RAB9ANPC1KMT2AMEN1PDE4B
SCHEMBL20023077 0.83 EGFR (0.45) RAB9ANPC1DPP4LMNAKMT2A
SCHEMBL20023036 0.83 TDP1 (0.61) RAB9ANPC1DPP4LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594563-B1 2-acylaminopropanol-type glucosylceramide synthase inhibitors GENZYME CORP (US) 2018-07-18 EP disclosed
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors ASAH2, GBA1, GAA USP5 3625/4885RAB9A 2280/4885NPC1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.